1. Home
  2. PIPR vs COGT Comparison

PIPR vs COGT Comparison

Compare PIPR & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Piper Sandler Companies

PIPR

Piper Sandler Companies

HOLD

Current Price

$377.84

Market Cap

5.8B

Sector

Finance

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$39.70

Market Cap

6.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PIPR
COGT
Founded
1895
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
6.5B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
PIPR
COGT
Price
$377.84
$39.70
Analyst Decision
Buy
Buy
Analyst Count
3
14
Target Price
$362.50
$32.08
AVG Volume (30 Days)
105.5K
2.2M
Earning Date
02-06-2026
02-24-2026
Dividend Yield
1.55%
N/A
EPS Growth
42.49
N/A
EPS
13.30
N/A
Revenue
$1,717,433,000.00
N/A
Revenue This Year
$17.96
N/A
Revenue Next Year
$14.78
N/A
P/E Ratio
$28.08
N/A
Revenue Growth
13.46
N/A
52 Week Low
$202.91
$3.72
52 Week High
$380.00
$43.73

Technical Indicators

Market Signals
Indicator
PIPR
COGT
Relative Strength Index (RSI) 63.07 61.99
Support Level $364.94 $37.70
Resistance Level $379.54 $40.40
Average True Range (ATR) 9.87 1.90
MACD 1.04 0.31
Stochastic Oscillator 92.65 83.19

Price Performance

Historical Comparison
PIPR
COGT

About PIPR Piper Sandler Companies

Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services followed by Equity financing.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: